Tyler Whisman

Tyler Whisman, PharmD, BCOP, is an experienced Medical Affairs leader with over 10 years of pharmaceutical expertise, particularly in oncology, hematology, and rare diseases. They have built and led high-performing field medical teams and successfully launched more than 12 innovative therapies, including the first FDA-approved CAR-T therapy, Kymriah. Tyler served in various leadership roles at Novartis Oncology, overseeing significant collaborations that improved patient access to critical medications for millions. Currently, they are a Medical Executive Director for National Accounts at Genentech, continuing to drive strategic initiatives in the field. Tyler holds a degree from the University of Kentucky.